NEW YORK, NY – 1/17/2017 (PRESS RELEASE JET) – TetraLogic Pharmaceuticals Corporation (“TetraLogic” or “Company”) today announced the appointment of Mr. Alexandre Zyngier to its Board of Directors and to its management. The appointment to the Board was effective on December 30, 2016, and, as of December 31, 2016 Mr. Zyngier is the sole director and officer of the Company.
Mr. Zyngier is a Managing Director and founder of Batuta Advisors, firm that pursues investment and advisory opportunities in the distressed and turnaround sectors. Mr. Zyngier has over 20 years of investment, strategy, and operating experience. He currently serves on the boards of directors of Atari SA, AudioEye Inc. (AEYE), GT Advanced Technologies Inc. and Torchlight Energy Resources, Inc (TRCH). Hewas previously Chairman of the Board of Vertis Inc., a director of Island One LLC and Executive Chairman of DTV America Corporation. Mr. Zyngier has worked as a Portfolio Manager, investing in public and private opportunities, at Alden Global Capital, Goldman Sachs & Co., Deutsche Bank Co. and as a sell-side distressed and event-driven analyst at CRT Capital Group. He was also a strategy consultant at McKinsey & Company. Prior to that, he was a technical brand manager at Procter & Gamble, focused on Latin America Beauty Care Products.
On December 29, 2016, TetraLogic announced completion of the sale to Medivir AB (Nasdaq Stockholm: MVIR-B) (“Medivir”) of its SMAC mimetic program, including their clinical stage asset birinapant, and topical HDAC inhibitor, remetinostat (SHAPE).
The Company has voluntarily delisted its Common Stock, from The Nasdaq Global Market and deregistered its Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended.